Eli Lilly to Acquire Narcolepsy Drug Maker Centessa for $6.3 Billion

The deal marks Lilly's latest move to expand its pharmaceutical pipeline and portfolio.

Mar. 31, 2026 at 2:49pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of premium, polished medical devices and pharmaceutical packaging arranged elegantly on a clean, monochromatic background, conceptually representing the corporate strategy and innovation behind sleep disorder treatments.Lilly's acquisition of Centessa Pharmaceuticals reflects the pharmaceutical industry's growing focus on developing new treatments for sleep disorders.Boston Today

Pharmaceutical giant Eli Lilly has reached an agreement to acquire Centessa Pharmaceuticals, a Boston-based biotech company developing treatments for narcolepsy and other neurological conditions. Lilly will pay an initial $6.3 billion in cash for Centessa, with the potential for an additional $1.5 billion in payments if certain regulatory milestones are met.

Why it matters

The acquisition reflects Lilly's strategy to bolster its drug development pipeline, particularly in the growing market for sleep disorder treatments. While past medications have focused on helping patients sleep better, newer drugs like Centessa's lead candidate aim to also keep people awake during the day, which could have applications for a wider range of neurological conditions.

The details

Centessa, a publicly traded company with operations in both Boston and the UK, does not currently have any approved drugs on the market. However, it has been conducting a mid-stage clinical trial for its lead narcolepsy drug candidate. The acquisition is expected to close before October, pending shareholder and regulatory approvals.

  • Eli Lilly reached the deal to acquire Centessa on March 31, 2026.
  • The acquisition is expected to be finalized before October 2026.

The players

Eli Lilly

A major pharmaceutical company headquartered in Indiana, best known for its weight-loss drug Zepbound/Mounjaro.

Centessa Pharmaceuticals

A Boston-based biotech company developing treatments for narcolepsy and other neurological conditions, which does not yet have any approved drugs on the market.

Got photos? Submit your photos here. ›

What’s next

The acquisition must still be approved by Centessa shareholders and regulators before it can be finalized.

The takeaway

Lilly's acquisition of Centessa reflects the pharmaceutical industry's increasing focus on developing new treatments for sleep disorders, which could have applications beyond just helping patients sleep better. The deal also highlights Lilly's strategy of expanding its drug pipeline through strategic acquisitions.